Alert Regarding Cisplatin-induced Severe Adverse Events in Cancer Patients with Xeroderma Pigmentosum

Xeroderma pigmentosum (XP) is a genetic disease in which DNA repair mechanisms are impaired. Cisplatin (CDDP) exerts cytotoxic effects by forming mainly intrastrand DNA cross-links, and sensitivity to CDDP depends on the DNA repair system. Several in vitro studies have suggested that treatment with CDDP may cause enhanced adverse events as well as anti-tumor activity in cancer patients with XP. This article is the first to describe two cancer patients with XP showing severe adverse events following CDDP-based chemotherapy. Physicians should pay attention when administering CDDP in cancer patients with XP.

[1]  E. Fadda,et al.  Role of the XPA protein in the NER pathway: A perspective on the function of structural disorder in macromolecular assembly , 2015, Computational and structural biotechnology journal.

[2]  J. Llorens,et al.  Cisplatin-Induced Ototoxicity: Effects, Mechanisms and Protection Strategies , 2015, Toxics.

[3]  Amit Kumar Srivastava,et al.  Enhanced expression of DNA polymerase eta contributes to cisplatin resistance of ovarian cancer stem cells , 2015, Proceedings of the National Academy of Sciences.

[4]  R. Stephanie Huang,et al.  Pharmacogenomics of Cisplatin Sensitivity in Non-small Cell Lung Cancer , 2014, Genom. Proteom. Bioinform..

[5]  M. Gregory,et al.  Structural and mechanistic studies of polymerase η bypass of phenanthriplatin DNA damage , 2014, Proceedings of the National Academy of Sciences.

[6]  V. Munford,et al.  DNA repair diseases: What do they tell us about cancer and aging? , 2013, Genetics and molecular biology.

[7]  S. Webb.  A Patient’s Journey : Xeroderma pigmentosum , 2008 .

[8]  Karl-Peter Hopfner,et al.  Bypass of DNA Lesions Generated During Anticancer Treatment with Cisplatin by DNA Polymerase η , 2007, Science.

[9]  M. Albertella,et al.  A role for polymerase eta in the cellular tolerance to cisplatin-induced damage. , 2005, Cancer research.

[10]  Shunqing Xu,et al.  Sensitization to the cytotoxicity of cisplatin by transfection with nucleotide excision repair gene xeroderma pigmentosun group A antisense RNA in human lung adenocarcinoma cells. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[11]  J. Crowley,et al.  Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: a Southwest Oncology Group study. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  P Chomy,et al.  Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.